| Literature DB >> 30642719 |
Katherine Fay1, Olivia Almendares2, Barbara Robinson-Dunn3, Stephanie Schrag4.
Abstract
Perinatal group B Streptococcus (GBS) disease prevention guidelines in 2010 allowed for processing of screening specimens by nucleic acid amplification tests (NAATs); however, the extent of NAAT use is unknown. A 2016 laboratory survey sent to 10 surveillance sites found that 18.7% of responding laboratories offered NAAT for GBS screening (antenatal only: 7.3%; intrapartum only: 4.1%; both: 3.4%).Entities:
Keywords: Antenatal; GBS; Intrapartum; NAAT; Screening
Mesh：
Year: 2018 PMID： 30642719 DOI： 10.1016/j.diagmicrobio.2018.11.026
Source DB: PubMed Journal: Diagn Microbiol Infect Dis ISSN： 0732-8893 Impact factor: 2.803